Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Renalytix ( (GB:RENX) ) has shared an announcement.
Renalytix PLC has announced that UBS Group AG’s trading book holdings in the company have fallen below 5%, exempting them from reporting obligations. This change in UBS’s holdings could impact Renalytix’s market dynamics and investor perceptions, as it reflects a shift in the investment strategy of a major financial institution.
More about Renalytix
Renalytix PLC operates in the healthcare industry, specializing in the development of artificial intelligence-enabled diagnostics for kidney disease. The company focuses on improving kidney health outcomes by providing advanced diagnostic solutions for early detection and risk assessment of kidney diseases.
YTD Price Performance: 13.75%
Average Trading Volume: 404
Technical Sentiment Signal: Buy
Current Market Cap: $38.63M
See more data about RENX stock on TipRanks’ Stock Analysis page.